推荐产品
等级
pharmaceutical primary standard
API类
nomegestrol
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O
InChI
1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1
InChI key
IIVBFTNIGYRNQY-YQLZSBIMSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Nomegestrol acetate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
Nomegestrol acetate (NOMAc) is a potent, highly selective progestogen, a full agonist at the progesterone receptor, with no or minimal binding to other steroid receptors. It shows potent antigonadotropic activity mediated at the hypothalamic and pituitary level with strong antiestrogenic effects and a partial antiandrogenic effect. NOMAc is used in various formulations as a contraceptive.
Progestogen, contraceptive
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
危险分类
Aquatic Acute 1 - Repr. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Harry A van Diepen
Reproductive biology and endocrinology : RB&E, 10, 85-85 (2012-10-10)
Nomegestrol acetate (NOMAC), a synthetic progestogen derived from 19-nor-progesterone, recently completed clinical trials for use with 17beta-estradiol in a new monophasic combined oral contraceptive. In this review, published as well as previously unpublished preclinical studies that detail the effects of
G André
Journal de gynecologie, obstetrique et biologie de la reproduction, 34(1 Pt 1), 69-84 (2005-03-16)
As the biological effects of progestins vary according to their molecular structure, it becomes essential to differentiate the various types of progestins, particularly with regard to the breast. The purpose of this review was to gather published data on the
J D Wagner et al.
The Journal of clinical endocrinology and metabolism, 83(3), 896-901 (1998-03-20)
We have previously shown that medroxyprogesterone acetate (MPA), either alone or combined with conjugated equine estrogens (CEE), significantly decreased insulin sensitivity (SI), compared with both untreated controls and those treated with CEE alone. The purpose of this study was to
J Shields-Botella et al.
The Journal of steroid biochemistry and molecular biology, 87(2-3), 111-122 (2003-12-16)
The specific pharmacological profile of the 19-norprogestin nomegestrol acetate (NOMAC) is, at least in part, defined by its pattern of binding affinities to the different steroid hormone receptors. In the present study, its affinity to the progesterone receptor (PgR), the
C Pélissier et al.
Annales d'endocrinologie, 64(3), 216-226 (2003-08-12)
Dyslipidemia is a cardiovascular risk factor which commonly develops during forty. In Europe, progestins are frequently prescribed for treatment of perimenopausal symptoms in women in this age group, as well as in combination with estrogen replacement therapy in non hysterectomised
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门